Acadian Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Acadian Asset Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-439,767	Closed	-$1.58M	–	2183
2019 Q1	$1.58M	Buy	439,767 +200,379	+84%	+$868K	0.01%	748
2018 Q4	$1.47M	Buy	239,388 +44,642	+23%	+$272K	0.01%	640
2018 Q3	$1.14M	Buy	194,746 +80,064	+70%	+$400K	﹤0.01%	692
2018 Q2	$487K	Buy	+114,682	New	+$578K	﹤0.01%	898
2017 Q3	–	Sell	-156,527	Closed	-$1.13M	–	1622
2017 Q2	$1.13M	Sell	156,527 -222,669	-59%	-$1.37M	0.01%	681
2017 Q1	$2.01M	Sell	379,196 -121,970	-24%	-$824K	0.01%	620
2016 Q4	$3.6M	Sell	501,166 -701,561	-58%	-$5.67M	0.02%	472
2016 Q3	$11.3M	Buy	+1,202,727	New	+$9.99M	0.06%	254

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Acadian Asset Management's PETX Position: Q2 2019 in Review

Acadian Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 439,767 shares — an estimated $1.58M sold.

Acadian Asset Management first reported a position in PETX in Q3 2016 and held it in 8 quarters. The position peaked at $11.3M in Q3 2016. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Acadian Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Acadian Asset Management sold 439,767 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $1.58M.
Acadian Asset Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 8 quarters.
Acadian Asset Management's Aratana Therapeutics, Inc. position peaked at $11.3M in Q3 2016.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Acadian Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.